Top 50 Companies in the Cancer Vaccine Market: Statistics Report Till 2035
RELEASE DATE: Aug 2025 Author: Spherical InsightsRequest Free Sample Speak to Analyst
Description
According to a research report published by Spherical Insights & Consulting, The Global Cancer Vaccine Market Size is projected to Grow from USD 11.21 Billion in 2024 to USD 36.32 Billion by 2035, at a CAGR of 11.28% during the forecast period 2025–2035. A cancer vaccination has been seen as a possible means of combating and eliminating antigens. The market is growing as a result of the aging population and growing awareness of cancer prevention and treatment.
Introduction
Cancer is regarded as one of the world's most complicated illnesses and is increasingly contributing to death. Research, development, manufacturing, and distribution of vaccine-based cancer treatments are the main focuses of the worldwide cancer vaccine market. In addition to preventing cancer, cancer vaccinations strengthen the body's defenses against the cells that cause cancer. The healthcare industry has been compelled to quickly implement cancer vaccinations due to the rise in cancer cases worldwide. The Hepatitis B vaccination and the Human Papillomavirus (HPV) vaccine are the two authorized cancer vaccines that are presently on the market. The HPV virus can be effectively prevented with the Papillomavirus (HPV) Vaccine.
Navigate Future Markets with Confidence: Insights from Spherical Insights LLP
The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.
Unlock exclusive market insights-Download the Brochure now and dive deeper into the future of the Cancer Vaccine Market.
Cancer Vaccine Market Size & Statistics
- The Market Size for Cancer Vaccine Was Estimated to be worth USD 11.21 Billion in 2024.
- The Market Size is Going to Expand at a CAGR of 11.28% between 2025 and 2035.
- The Global Cancer Vaccine Market Size is anticipated to reach USD 36.32 Billion by 2035.
- North America is expected to generate the highest demand during the forecast period in the Cancer Vaccine Market
- Asia Pacific is expected to grow the fastest during the forecast period in the Cancer Vaccine Market.
Regional growth and demand
Asia Pacific is expected to grow the fastest during the forecast period in the cancer vaccine market. The market is growing because of the region's large population and the rising number of cancer patients there. The aging population and changing lifestyles are contributing factors to the market expansion in Asia Pacific, as are increased investments in R&D. Furthermore, it is anticipated that the region's expanding healthcare system would further increase the patient base's access to these vaccines. The market's expansion is also fueled by partnerships between pharmaceutical companies in Asia Pacific and academic institutions and research facilities.
North America is expected to generate the highest demand during the forecast period in the cancer vaccine market. It is anticipated that the region will continue to dominate for the duration of the prediction. The established North American healthcare system, which encourages cancer vaccination, is credited with the region's dominance. Additionally, the region's increasing cancer incidence contributes to the demand for cancer vaccinations. Another factor contributing to the market's expansion is the opportunity for researchers and developers to invest in the development of novel cancer vaccines.
Top 10 trends in the Cancer Vaccine Market
- mRNA-based cancer vaccine development
- Personalized neoantigen vaccines
- AI-driven cancer vaccine design and discovery
- Expansion of therapeutic cancer vaccines
- Combination therapies with immune checkpoint inhibitors
- Accelerated regulatory approvals and fast-tracking
- Strategic partnerships, collaborations, and M&A activity
- Advancements in delivery platforms (nanotechnology, lipid nanoparticles)
- Increasing patient access via supportive reimbursement
- Growth in the Asia-Pacific region and emerging markets
1. mRNA-based cancer vaccine development
mRNA platforms are revolutionizing how cancer vaccines are developed by enabling rapid, scalable, and precise instruction to immune cells. These vaccines allow companies to target tumor-specific antigens effectively and are moving quickly through clinical trials for cancers like melanoma and lung cancer. Major biopharmas (e.g., Moderna, BioNTech) are investing heavily in this area, spurred by breakthrough designations and promising results.
2. Personalized neoantigen vaccines
The ability to tailor vaccines using neoantigens—mutations unique to individual tumors—represents a shift towards true precision medicine. By leveraging advanced sequencing and bioinformatics, each patient’s vaccine can better trigger a targeted immune response, improving the chances of tumor remission with fewer side effects. This approach is frequently paired with mRNA technology and immune checkpoint inhibitors.
3. AI-driven cancer vaccine design and discovery
Artificial intelligence accelerates vaccine development by predicting which tumor antigens will best stimulate an immune response. AI is used for analyzing genomic data, designing peptides, optimizing clinical trial protocols, and improving manufacturing efficiency. This streamlining leads to higher success rates and reduced costs.
4. Expansion of therapeutic cancer vaccines
Therapeutic cancer vaccines, administered after diagnosis to treat existing cancers, are rapidly evolving for a wider range of tumors (melanoma, lung, prostate, pancreatic, colorectal). Researchers are moving beyond preventive vaccines (HPV, HBV) to innovative therapeutics that harness the immune system’s power to attack and eliminate cancer cells.
5. Combination therapies with immune checkpoint inhibitors
The use of cancer vaccines together with checkpoint inhibitors enhances treatment effectiveness by overcoming tumor immune evasion. This synergistic approach is demonstrating increased tumor responses and is now a major area in clinical development, leading to more robust immunotherapy regimes and fueling demand for combination treatment strategies
Empower your strategic planning:
Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the cancer vaccine market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.
Top 25 Companies Leading the Cancer Vaccine Market
- BioNTech SE
- Moderna Inc.
- CureVac AG
- Gritstone Bio Inc.
- Sanofi (Translate Bio)
- Candel Therapeutics
- Elicio Therapeutics
- Evaxion
- Immunomic Therapeutics
- Imugene
- Infinitopes
- Nouscom
- OSE Immunotherapeutics
- Scancell
- Takis
- VacV Biotherapeutics
- BioNTech US (subsidiary)
- Agenus Inc.
- Vaccibody (Nykode Therapeutics)
- OncBioMune Pharmaceuticals
- BlueWillow Biologics
- Vaccinex
- CellDex Therapeutics
- Bavarian Nordic
- Inovio Pharmaceuticals
1. BioNTech SE
Headquarters: Mainz, Germany
BioNTech SE is a trailblazer in mRNA-based therapeutics and a top player in the cancer vaccine market. Headquartered in Mainz, Germany, the company’s groundbreaking research focuses on personalized neoantigen vaccines, leveraging advanced genomics and artificial intelligence for antigen discovery. BioNTech collaborates with leading pharma companies and regulatory agencies to accelerate development, targeting major cancers like melanoma and lung cancer. Its scalable platforms enable rapid vaccine design cycles, directly addressing current market trends in cancer immunotherapy. BioNTech’s commitment to innovation, clinical excellence, and individual patient solutions positions the company at the forefront of cancer vaccine advances, reinforcing its role as a driving force in global oncology.
2. Moderna, Inc.
Headquarters: Cambridge, Massachusetts, USA
Moderna, Inc. is a pioneer in mRNA technology, revolutionizing the cancer vaccine market from its headquarters in Cambridge, Massachusetts. The company’s dynamic oncology pipeline features highly personalized cancer vaccines designed to activate specific immune responses against tumor cells. By integrating AI-driven antigen selection and combination therapies with immune checkpoint inhibitors, Moderna demonstrates leadership in precision medicine for cancers such as melanoma. Strategic partnerships and regulatory momentum accelerate the market reach of Moderna’s innovative therapies. Their scalable mRNA platform exemplifies market trends, focusing on rapid development, personalized immunotherapy, and robust clinical performance in cancer treatment.
3. CureVac AG
Headquarters: Tübingen, Germany
CureVac AG emerges as a vanguard in mRNA-based cancer therapeutics, with its headquarters in Tübingen, Germany. The company’s proprietary RNA technology aims to encode tumor-specific antigens, harnessing advanced delivery platforms and bioinformatics to drive personalized immunotherapy. CureVac targets an array of solid and hematologic malignancies, emphasizing scalable, cost-effective vaccine development. Collaborations with global institutions underline its commitment to next-generation cancer care. By innovating in personalized neoantigen vaccines and clinical validation, CureVac aligns with major trends in individualized, high-impact cancer treatment and is shaping the future of the cancer vaccine market.
4. Gritstone Bio, Inc.
Headquarters: Emeryville, California, USA
Gritstone Bio, Inc. stands out in the cancer vaccine space with its focus on precision immunotherapies, headquartered in Emeryville, California. Employing artificial intelligence to identify patient-specific neoantigens, Gritstone develops both mRNA and viral-vector vaccines that deliver personalized cancer solutions. Their leading candidates address high-need cancers like lung and gastrointestinal malignancies, pairing vaccines with checkpoint inhibitors for enhanced effectiveness. Gritstone’s approach reflects key market trends—personalized treatments, combination therapies, and AI-driven design—helping to propel cancer vaccine innovation toward commercialization and impactful patient outcomes.
5. Sanofi (Translate Bio)
Headquarters: Paris, France
Sanofi, strengthened by acquiring Translate Bio, anchors its leading-edge research in Paris, France. The company integrates Translate Bio’s expertise in mRNA cancer vaccine technology to develop targeted immunotherapies for a range of tumors. By advancing lipid nanoparticle delivery platforms and expanding global partnerships, Sanofi enhances both R&D and patient access within the cancer vaccine market. Their pipeline focuses on rapid, precise mRNA instruction for anti-tumor activity, aligning closely with emerging trends like global expansion, regulatory innovation, and personalized medicine in cancer care.
Are you ready to discover more about the cancer vaccine market?
The report provides an in-depth analysis of the leading companies operating in the global cancer vaccine market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardized format that includes:
Company Profiles
- BioNTech SE
- Business Overview
- Company Snapshot
- Products Overview
- Company Market Share Analysis
- Company Coverage Portfolio
- Financial Analysis
- Recent Developments
- Merger and Acquisitions
- SWOT Analysis
- Moderna Inc.
- CureVac AG
- Gritstone Bio Inc.
- Sanofi (Translate Bio)
- Candel Therapeutics
- Elicio Therapeutics
- Evaxion
- Immunomic Therapeutics
- Others.
Conclusion
The cancer vaccine market is rapidly transforming through cutting-edge technologies such as mRNA platforms and AI-driven design, reflecting strong momentum in personalized and scalable therapies. Leading companies are successfully integrating precision medicine with innovative delivery and combination strategies, enhancing treatment efficacy and patient outcomes. Strategic partnerships and global expansions are fueling the market’s growth and accelerating regulatory approvals for promising candidates. As consumer awareness and demand rise, companies are intensifying research and collaborations, making advanced cancer vaccines increasingly accessible worldwide.
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?